Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—is heading for the exit.

Employers have the opportunity to lead by example: to stop treating obesity as invisible and start addressing it as the ...

After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs, some U.S.

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

Type 2 Diabetes market is projected to grow at a CAGR of 8.2% through 2033. Key drivers include advancements in ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

A miracle drug just wiped out WeightWatchers International’s (WW) 60-year empire. Here’s how Ozempic disrupted the weight ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...